Provexis and DSM Nutritional Products have teamed up for the second time to research, develop and bring to market a non-dairy protein peptide with glycaemic response potential.
Biotech start-up Provexis says it will commence two clinical trials in 2011 – one in the area of cardiovascular inflammation, the other in treatment of “hospital superbug” c.difficile.
Functional ingredient innovator Provexis has secured a new 12-month
deal with Unilever to investigate the use of its Fruitflow
technology in the multinational's spreads brands.
Provexis is seeking to raise new funds to bolster its working
capital, after depleting its coffers with the extended timeline for
developing an advanced form of its Fruitflow technology.
Extracts from tomatoes offer heart health benefits by reducing the
accumulation of platelets that lead eventually to blood clots,
heart attacks and strokes, say two complimentary studies from the
UK.
The strategy of demonstrating the potential of new technology with
an own-brand launch in order to garner interest from major industry
players seems to be paying off for Provexis, which has progressed
with global licensing discussions...
UK-based Nutrinnovator, a start-up company making functional foods,
has suspended its share listing to raise £10 million for a reverse
takeover of nutraceutical developer Provexis.
Provexis, the UK company whose main product CardioFlow, a novel
extract from tomato, has been shown to be beneficial to the heart,
has been given a major boost with the addition of a leading British
scientist to its Scientific Advisory...
